ReviewVirchows Archiv : an international journal of pathology2012
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
Review in Virchows Archiv : an international journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.Translational oncology · 2026Article
- A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing.Pathology oncology research : POR · 2025Article
- The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment-Literature Review.Biomedicines · 2024Review
- DiscordantInternational journal of molecular sciences · 2024Article
- Navigating Quality Assessment Hurdles in Clinical Laboratory Services: A Comprehensive Review in Resource-Limited Settings.Risk management and healthcare policy · 2024Review
- False positivity in break apart fluorescence in-situ hybridization due to polyploidy.Translational lung cancer research · 2023Article
- Article
- The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories.Cancers · 2022Review
- Article
- Molecular diagnosis in non-small-cell lung cancer: expert opinion onJournal of clinical pathology · 2022Review
- A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients.Thoracic cancer · 2021Article
- Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients.Cancers · 2021Review
- Testing forOncoTargets and therapy · 2021Review
- [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.Molecules (Basel, Switzerland) · 2020Review
- Molecular profiling for precision cancer therapies.Genome medicine · 2020Review
- Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer.Journal of Cancer · 2020Article
- Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.Oncology reports · 2020Article
- Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?Cancer medicine · 2019Article
- Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature.Translational oncology · 2019Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.